Read more: HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Read more: HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
Read the original post: Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
See the rest here: QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency
View post: Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
More: Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
Read the original post: Telix Files Registration Statement for Proposed Initial Public Offering in the United States
Read the original post: Tilray Brands Announces At-The-Market Program to Fund Strategic and Accretive Acquisitions and Accelerate Expansion Plan Upon U.S. Cannabis...
Visit link: Intercept Presents New Data Demonstrating the Impact of OCA-Bezafibrate Combination Therapy on ALP and Metabolic Outcomes After Six Months of...
See the article here: Dyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ET
Oncol Lett.
Recent Comments